N-甲基-N-丙-2-炔基己烷-2-胺盐酸盐 | 143347-04-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基-N-丙-2-炔基己烷-2-胺盐酸盐
• 中文别名: 3,4-呋喃二胺,四氢-,顺-(9CI)
• 英文名称: N-(2-hexyl)-N-methylpropargylamine
• 英文别名: N-2-Hexyl-N-methylpropargylamine；N-methyl-N-prop-2-ynylhexan-2-amine
• CAS: 143347-04-0
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: OPNHJZDMXLCVAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-己醇 在 二溴亚砜 、 氯化亚砜 、 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 168.0h， 生成 N-甲基-N-丙-2-炔基己烷-2-胺盐酸盐
  参考文献：
  名称：

  Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors

  摘要：

  A series of aliphatic propargylamine derivatives has been synthesized. Some of them possess highly potent, irreversible, selective, inhibitory activity toward monoamine oxidase B (MAO-B). The potency of the inhibitors is related to chain length and substitution of a hydrogen on the terminal carbon of the aliphatic chain. MAO inhibitory activity as assessed in vitro increased as the aliphatic carbon chain length increased. Substitution of a hydrogen by hydroxyl, carboxyl, or carbethoxyl groups at the aliphatic chain terminal or replacement of the methyl group on the nitrogen atom by an ethyl group considerably reduced the inhibitory activity. Stereospecific effects were observed with the R-(-)-enantiomer being 20-fold more active than the S-(+)-enantiomer. Inhibitors with relatively short carbon chain lengths (i.e. four to six carbons) were found to be more potent than those with longer chains in inhibiting brain MAO-B activity in vivo especially after oral administration. Chronic administration of low doses of the aliphatic propargylamines caused a slight cumulative inhibition of MAO-A activity in the mouse brain. These MAO-B inhibitors appear to be nontoxic, and they do not possess an amphetamine-like moiety in their structure as is the case for deprenyl. We expect that these aliphatic propargylamines may be useful in the treatment in certain neuropsychiatric disorders.

  DOI：

  10.1021/jm00098a017

文献信息

• Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents
  申请人：Dyck E. Lillian

  公开号：US20050159393A1

  公开（公告）日：2005-07-21

  Novel compounds of the formula I are described: wherein: R 1 =(CH 2 ) m CH 3 where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, R 2 =H, CH 3 or CH 2 CH 3 R 3 =H or CH 3 R 4 =H or CH 3 R 5 =lower alkyl having from 1 to 5 carbon atoms n is an integer in the range from 1 to 3, and X is carboxyl (COOH) or carbalkoxy (COOR 5 ), cyano (C≡N), phosphonic acid (PO 3 H 2 ), phosphonate ester (PO 3 [R 5 ] 2 ) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R- or S-configuration in which R 3 =R 4 =R 5 =H, R 2 =CH 3 and R 1 is a saturated aliphatic chain of one to five carbon atoms. The compounds are useful as cellular rescue agents.

  描述了公式I的新化合物：其中：R1=(CH2)mCH3，其中m为0或在1到16范围内的整数，或者为具有2到17个碳原子的烯基、炔基、烷氧基、烷基硫醚或烷基亚砜基团，R2=H、CH3或CH2CH3，R3=H或CH3，R4=H或CH3，R5=具有1到5个碳原子的低碳基，n为1到3范围内的整数，X为羧基（COOH）或羧酰氧基（COOR5）、氰基（C≡N）、膦酸（PO3H2）、膦酸酯（PO3[R5]2）或5-四唑，并且其药学上可接受的盐。优选，这些化合物是R-或S-构型的光学纯对映体，其中R3=R4=R5=H，R2=CH3，R1是由一到五个碳原子组成的饱和脂肪链。这些化合物可用作细胞救助剂。
• Deprenyl compounds for treating Multiple Sclerosis
  申请人：Shankar, L. Sai Latha

  公开号：EP1621190A1

  公开（公告）日：2006-02-01

  A method for increasing the survival of oligodendrocytes, comprising administering an effective amount of a deprenyl compound to a patient such that survival of oligodendrocytes is increased.

  一种提高少突胶质细胞存活率的方法，包括向患者施用有效量的去甲肾上腺素化合物，从而提高少突胶质细胞的存活率。
• Compositions and Methods for Treatment of Cardiovascular Disorders and Diseases
  申请人：Technion Research & Development Foundation Ltd.

  公开号：EP2433626A1

  公开（公告）日：2012-03-28

  The present invention is directed to the use of S-(-)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for prevention and/or treatment of a cardiovascular disease or disorder.

  本发明涉及 S-(-)-N-丙炔基-1-氨基茚满或其药学上可接受的盐用于制备预防和/或治疗心血管疾病或紊乱的药物组合物。
• Method for treating multiple sclerosis
  申请人：——

  公开号：US20030078295A1

  公开（公告）日：2003-04-24

  Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis.

  本发明公开了提高少突胶质细胞存活率的方法。本发明的方法可用于治疗多发性硬化症。
• Methods for treating multiple sclerosis
  申请人：Shankar Latha L. Sai

  公开号：US20050004229A1

  公开（公告）日：2005-01-06

  Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis.

  本发明公开了提高少突胶质细胞存活率的方法。本发明的方法可用于治疗多发性硬化症。